News
AXGN
34.00
+9.71%
3.01
Weekly Report: what happened at AXGN last week (0330-0403)?
Weekly Report · 2d ago
Axogen Price Target Maintained With a $40.00/Share by Canaccord Genuity
Dow Jones · 03/30 15:50
Axogen Is Maintained at Buy by Canaccord Genuity
Dow Jones · 03/30 15:50
AxoGen (AXGN) Receives a Buy from Canaccord Genuity
TipRanks · 03/30 13:36
Weekly Report: what happened at AXGN last week (0323-0327)?
Weekly Report · 03/30 09:21
Axogen Insider Sale of 5,221 Shares Follows 20% Revenue Growth in 2025. Here's What to Know
NASDAQ · 03/24 19:19
Weekly Report: what happened at AXGN last week (0316-0320)?
Weekly Report · 03/23 09:20
AMG TimesSquare Small Cap Growth Fund Q4 2025 Performance Insights
Seeking Alpha · 03/18 05:35
NervGen Pharma: I See Promise, But The Clock Is Ticking (Rating Downgrade)
Seeking Alpha · 03/17 16:19
Weekly Report: what happened at AXGN last week (0309-0313)?
Weekly Report · 03/16 09:20
Weekly Report: what happened at AXGN last week (0302-0306)?
Weekly Report · 03/09 09:20
Axogen Inc. Publishes Corporate Presentation on Advancing Peripheral Nerve Repair Standard of Care
Reuters · 03/04 19:23
AxoGen Earnings Call Highlights Growth, Biologic Pivot
TipRanks · 03/04 00:24
Weekly Report: what happened at AXGN last week (0223-0227)?
Weekly Report · 03/02 09:20
AxoGen (AXGN) Receives a Buy from H.C. Wainwright
TipRanks · 02/27 11:36
Axogen Q4: EPS Miss Amid Biologics Transition
Seeking Alpha · 02/25 10:23
Axogen targets at least 18% revenue growth in 2026 as BLA milestone strengthens market position
Seeking Alpha · 02/24 16:38
Axogen Is Maintained at Market Outperform by Citizens
Dow Jones · 02/24 14:44
Citizens Maintains Market Outperform on Axogen, Raises Price Target to $42
Benzinga · 02/24 14:35
Axogen posts Q4 revenue of USD 59.9 million, up 21.3% YoY
Reuters · 02/24 13:16
More
Webull provides a variety of real-time AXGN stock news. You can receive the latest news about Axogen Inc through multiple platforms. This information may help you make smarter investment decisions.
About AXGN
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating.